NCT03328078 2026-04-16
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Phase 1/2 Recruiting
Clinical Trials
25 trialsNCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT03016377 2025-10-27
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT05963217 2025-07-02
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
Phase 1 Recruiting
NCT04996875 2025-05-30
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT03155191 2024-11-20
TBI-1501
Takara Bio Inc.
Phase 1/2 Active not recruiting
NCT03743246 2024-08-15
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
Phase 1/2 Terminated
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT04601584 2024-03-06
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Phase 1/2 Unknown
NCT05066165 2023-12-28
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
Intellia Therapeutics
Phase 1/2 Terminated
NCT02733042 2023-11-18
FUSION NHL 001
Celgene
Phase 1/2 Completed
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT00772486 2021-09-22
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
Memgen, Inc.
Phase 1 Completed
NCT02799147 2020-11-23
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
St. Petersburg State Pavlov Medical University
Phase 1/2 Completed
NCT02670564 2019-04-16
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)
Swiss Pediatric Oncology Group
Phase 4 Recruiting
NCT02627573 2019-04-05
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
St. Petersburg State Pavlov Medical University
Phase 2 Terminated
NCT02657447 2019-01-10
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Nordic Nanovector
Phase 1 Withdrawn
NCT02294552 2018-01-16
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
St. Petersburg State Pavlov Medical University
Phase 2 Completed
NCT00000591 2016-04-15
T-Cell Depletion in Unrelated Donor Marrow Transplantation
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT00783588 2008-10-31
A Phase I Extension Trial of Repeated Infusions of ISF35
Memgen, Inc.
Phase 1 Completed
NCT00779883 2008-10-24
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
Memgen, Inc.
Phase 1 Completed